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Objective: this prospective study aimed to assess the quality of life related to health (QLRH) of 
patients with lung cancer after chemotherapy treatment. Method: The QLRH was assessed using 
the questionnaires Quality-of-Life Questionnaire-Core 30 (QLQ-C30) and Lung Cancer Module 
(LC13), version 3.0. Results: the sample was made up of 11 women and 19 men, with an 
average age of 68 years (51-87 years). After the chemotherapy treatment, the authors observed 
a clinically-relevant improvement in general quality of life, as well as in the symptoms of dyspnea, 
insomnia, hemoptysis, cough, thoracic pain, pain in the arm/shoulder, and financial difficulty. 
There was a worsening on the functional scale which assesses role performance and symptoms 
of fatigue, nausea and vomiting, sensory neuropathy, pain in other parts, constipation, loss of 
appetite and alopecia. Conclusion: although the patients have an improvement of their QLRH and 
symptoms related to the lung cancer after the chemotherapy treatment, there was a worsening 
of the symptoms which resulted from the toxicity of the chemotherapy medications.
Descriptors: Quality of Life; Carcinoma, Bronchogenic; Drug Therapy.
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Introduction
Worldwide, lung cancer is the most common type of 
cancer. In Brazil, it has become one of the most important 
public health problems, and is among the cancers which 
cause the greatest mortality among men. It is estimated 
that in 2012, there were 17,210 new cases of lung cancer 
among men, and 10,110 among women. This type of 
cancer is considered an aggressive illness and is generally 
detected in the advanced stages, as the symptoms in the 
initial stages of the disease are not common. As a result, 
lung cancer remains a highly lethal disease, in which over 
86% of the patients die in the first five years following 
diagnosis. Lung cancer does not present as a disease with 
uniform behavior, as it has different histological types with 
different biological activities and aggressiveness, with 
non-small-cell lung carcinoma being the most frequent 
type of lung cancer(1-2).
The value of chemotherapy in the treatment of 
advanced non-small cell lung cancer has been proven 
over the last decade, there being an increase in survival 
in comparison with palliative care. The benefit, however, 
is modest, as chemotherapy’s impact on quality of life 
remains an unknown(3-4). 
All this effort from science and technology in 
prolonging life is significant, but cannot be viewed in 
isolation. It is fundamental that the prolonging of 
survival should be associated with better quality of life 
(QL)(5). Quality of life related to health (QLRH) is “the 
value assigned to duration of life as modified by the 
impairments, functional states, perceptions, and social 
opportunities that are influenced by disease, injury, 
treatment, or policy(6)”. 
Due to the large number of symptoms and morbidities 
caused by lung cancer, the assessment of QLRH has 
become an essential component in the management 
of cancer, and its evaluation must be incorporated as a 
matter of routine, helping in the comparison of different 
therapeutic regimes, and consequently in the choice of 
the most appropriate mode(7). 
In Brazil, there have been few scientific works 
discussing the quality of life of patients with lung 
cancer undergoing chemotherapy treatment. By far 
the majority of studies have been undertaken in other 
countries, principally in developed countries which, due 
to the cultural and socio-economic differences, do not 
reflect the context of Brazilian patients. The present 
study’s objective was to assess the changes in the 
QLRH of patients with lung cancer before and after 
chemotherapy treatment. 
Methods
This is an observational and cross-sectional study, 
carried out in a public hospital in São Paulo, between 
June 2007 and February 2009. 
The study included a convenience sample made up 
of 30 patients who met the following inclusion criteria: 
age over 18 years old, a diagnosis of non-small cell 
lung cancer confirmed by pathology, staging III-B or IV, 
indicated for treatment with chemotherapy exclusively, 
a Karnofsky Index of over 50 including patients without 
complaints, with moderate symptoms, or who need 
occasional care, but who are still capable of meeting 
the majority of their needs. Patients were excluded 
who had a Karnofsky Index below 50 - as these require 
considerable care and frequent medical care, those with 
a prior diagnosis of cancer, and the patients who refused 
to participate in any phase of the study. The research was 
approved by the Research Ethics Committee and all the 
patients signed the terms of Free and Informed Consent. 
The instruments included in this study included 
a socio-demographic and clinical form, the Karnofsky 
functional performance scale, and the QLRH 
questionnaires from the European Organization for 
Research and Treatment of Cancer (EORTC), these being 
the Quality of Life questionnaire-core 30 (QLQ-C30) and 
the Lung Cancer Module (LC-13), version 3.0(8-9). The 
QLRH questionnaires were translated and validated for 
the Portuguese language and their use was authorized 
by the EORTC(10-11).
Data collection was carried out in an environment 
set aside for the purpose, on a date coinciding with 
the patient’s appearance in hospital, prior to either 
the meeting with the doctor or the procedure. In the 
first phase of data collection, the Karnofsky scale, the 
socio-demographic and clinical form, and the QLRH 
questionnaires were administered to all the patients 
with suspected lung cancer. After the diagnosis had 
been confirmed and treatment prescribed, the disease’s 
clinical progression was monitored, and after the third 
cycle of chemotherapy, the QLRH questionnaires were 
administered for the second time. The institution’s 
chemotherapy protocol has, on average, six cycles, 
with all patients being re-assessed after the third cycle 
of chemotherapy. The assessment of survival was 
undertaken in February 2009, by checking the hospital’s 
records of deaths. In the case of patients for whom 
there was no hospital record of death, an active search 
was made by telephone to verify the progression of the 
disease. 
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For characterization of the sample, the following 
variables were collected from the socio-demographic 
and clinical questionnaires: sex, age, level of schooling, 
marital status, religion, employment situation, whether 
the person smoked, initial symptoms, histological 
diagnosis, staging, chemotherapy regime, tumor 
response and survival. 
The Karnofsky Scale comprises a numerical 
scale (10-100) which assesses the patients’ physical 
limitations, signs and symptoms, need for care and 
general status. On the scale, the higher the score is, 
the better the functional performance, and the lower the 
score, the more debilitated the patient is(8).
The QLQ-C30 is a questionnaire made up of 30 
questions distributed in five scales of functionality, 
representing the domains of the QLRH (physical function, 
cognitive function, emotional function, social function and 
role performance); three scales of symptoms (fatigue, 
pain, nausea and vomiting); six further items assessing 
symptoms commonly associated with cancer patients 
(dyspnea, lack of appetite, insomnia, constipation 
and diarrhea); a scale for global quality of life and 
health, and a scale for assessing the financial impact 
of the treatment and of the disease. The QLQ-LC13 is a 
complementary module of the QLQ-C30, specifically for 
evaluating quality of life in patients with lung cancer. The 
questionnaire is made up of 13 questions which assess 
the symptoms associated with lung cancer, by means of 
a scale for dyspnea and other items (cough, hemoptysis, 
dyspnea and pain in a specific place); effects related to 
the treatment (pain in the throat, dysphagia, sensory 
neuropathy and alopecia) and treatment of the pain(9). 
The values for scoring the scales and the individual 
items of the QLQ-C30 and LC13 vary from 0 to 100. In 
the interpretation of the functional scales and general 
state of health/QL, the higher the score, the better 
the functional index and QL, therefore, positive ∆ = 
worsening of functional level/QL, while negative ∆ = 
improvement of functional level and QL. For the scales or 
items which assess the symptoms, the higher the score, 
the higher the indexes of the symptoms and problems, 
therefore positive ∆ = improvements in symptoms, 
while negative ∆ = worsening of symptoms(9).
The data was stored and analyzed using the SPSS 
(Statistical Package for the Social Sciences), program, 
version 13.0. The descriptive analyses were undertaken 
to characterize the sample and included the calculation 
of absolute frequency, percentage, and measurements 
of central tendency. For the comparative analysis of the 
QLRH before and after the chemotherapy treatment, the 
paired t test was used, due to the normal distribution 
of the data. The Kaplan-Meier method was used for the 
survival curve.  
As a measure of reliability, the Cronbach alpha 
co-efficient was calculated, to assess the internal 
consistency of the QLRH assessment questionnaires, in 
which a value equal or superior to 0.70 was considered 
adequate to ensure the scale’s good reliability.  The test 
showed satisfactory reliability for the scales of global 
quality of life and health, role performance, emotional 
function, social function, fatigue and dyspnea. The 
scales for pain, cognitive function, the scales for physical 
function and nausea and vomiting had a dissatisfying 
performance, with values below 0.70 (Table 1). One of 
the factors which may have led to the low consistency 
was the number of items on the scale, as the Cronbach 
alpha is fairly sensitive to the number of items on the 
scale and to the number of points it has(12).
Table 1 – Test of the reliability of the QLQ-C30 and LC-13 instruments administered to thirty patients with bronchial 
carcinoma, São Paulo, SP, Brazil, 2012
Scale Nº items N Cronbach alpha*
Global Health/QL QL2 2 30 0.94
Social Function SF 2 30 0.94
Dyspnea LCDY 3 30 0.76
Role Performance RF2 2 30 0.73
Emotional Function EF 4 30 0.73
Fatigue FA 3 30 0.71
Physical Function PF2 5 30 0.63
Pain PA 2 30 0.63
Nausea and Vomiting NV 2 30 0.60
Cognitive Function CF 2 30 0.56
* Cronbach alpha test
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For interpretation of the clinically-relevant 
results, the authors took into account the delta (∆) 
value corresponding to the average score of the 
QLRH measurements prior to chemotherapy minus 
the average score after chemotherapy. Delta values 
varying between 5 and 10 points between the groups 
were defined as clinically-relevant, while values over 
10 points represented a large change in the domain 
assessed(13-14). The confidence interval used was 95%. 
For this study, a level of significance below 0.05 was 
considered statistically-significant. 
Table 2 - Demographic and clinical data of the patients with lung cancer, São Paulo, SP, Brazil, 2012
Characteristics N=30
Age (years)* 68 (8.8) / 51-87 years
Sex†
Female/ Male 11(37%) / 19(63%)
Race†
White/ Not white 25(83%) / 05(17%)
Smoking†
Smokers/ Ex-smokers/ Non-smokers 12(40%) / 13(43%) / 05(17%)
Initial symptoms†
Dyspnea / Weight loss / Cough 17(57%) / 11(37%) / 23(77%)
Karnofsky*
Pre-chemotherapy / Post-chemotherapy 76 (8) / 72 (8)
Staging†
IIIB/IV 14(47%) / 16(53%)
Chemotherapy Protocol
Cisplatin + Gemcitabine 19 (63%)
Gemcitabine + Carboplatin 6 (20%)
Carboplatin + Paclitaxel 2 (07%)
Carboplatin + Pemetrexed 2 (07%)
Paclitaxel + Gemcitabine 1 (03%)
Tumor response
Response/Without response 16(53%) / 14(47%)
* Average, Standard Deviation and Minimum and Maximum Values; †Frequency and Percentages
Results
In the first phase of the study, 61 patients were 
assessed, with 31 being excluded subsequently: 23 
patients died before completing the second phase of the 
study; 6 patients refused to participate in the study (4 in 
the first phase and 2 in the second); a further 2 patients 
did not conclude the second phase of the research 
because they had chosen to carry out the treatment in 
another service. The principal characteristics of the 30 
patients who concluded the study are shown in Table 2. 
The Karnofsky Index had a median of 80 points 
before treatment and a median of 70 points after the 
treatment. In the assessment of the Karnofsky scale, 
6.7% of the patients progressed with an improvement in 
the Performance Status, 53.3% of the patients remained 
stable, and 40% presented a statistically-significant 
worsening (z=2.69, p=0.007, Wilcoxon test).
The results of the assessment of the QLRH domains, 
evaluated by the QLQ-30 questionnaire, before and 
after the third cycle of chemotherapy treatment, are 
presented in Table 3. One may observe that after the 
third cycle of chemotherapy, there was a clinically-
relevant improvement in quality of life (-7.5 points), 
as well as in the symptoms of dyspnea (15.5 points 
and p=0.037), insomnia (14.4 points), and financial 
difficulties (5.5 points). After chemotherapy treatment, 
a worsening was observed in the symptoms of fatigue 
(-5.9 points) and nausea and vomiting (-8.9 points). 
The symptoms of constipation and loss of appetite were 
the most intense with variation from -16.7 and -17.8 
points. There was a worsening in the functional scale 
which assesses role performance, with 5.6 points.  
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Table 4 presents the data from the average scores 
of the specific questionnaire QLQ-L13 before and 
after the third cycle of chemotherapy treatment. In 
the assessment of the quality of life related to health, 
with the lung-cancer-specific questionnaire, there was 
improvement in the symptoms of hemoptysis (8.8 
points and p=0.043), cough (8.9 points), thoracic pain 
(10.0 points) and pain in the arm/shoulder (12.3 points) 
after chemotherapy treatment. In contrast, there was 
a worsening of alopecia (-24.5 points and p=0.000), 
sensory neuropathy (-8.9 points) and pain in other parts 
(-5.6 points).
Pre-chemotherapy
N=30
Post-chemotherapy
N=30 ∆ t* p
Mean SD Mean SD
Dyspnea 38.8 39,2 23.3 26.4 15.5† 2.19 0.037‡
Insomnia 36.6 39,4 22.2 33.1 14.4† 1.65 0.108
Role Performance 70.0 27,8 64.4 37.3 5.6† 0.62 0.538
Financial Difficulties 26.6 34,3 21.1 34.4 5.5† 0.694 0.493
Social Function 78.3 18,6 73.8 31.1 4.5 0.75 0.455
Physical Function 72.4 19,4 68.2 16.0 4.2 1.33 0.191
Cognitive Function 78.8 26.9 76.6 25.7 2.2 0.55 0.580
Pain 23.8 26.1 23.3 30.1 0.5 0.079 0.937
Emotional Function 66.9 25.3 68.6 25.9 -1.7 -0.320 0.751
Diarrhea 1.1 6.0 5.5 15.3 -4.4 -1.43 0.161
Fatigue 30.0 27.5 35.9 30.1 -5.9† -0.79 0.431
General State of Health/QL 58.3 23.9 65.8 23.6 -7.5† -1.52 0.139
Nausea and Vomiting 7.2 15.5 16.1 24.9 -8.9† -1.72 0.096
Constipation 18.8 27.2 35.5 39.0 -16.7† -1.94 0.062
Loss of Appetite 23.3 36.2 41.1 41.6 -17.8† -1.88 0.069
Table 3 – Comparison of Mean Score of the QLQ-C30 Pre- and Post-Chemotherapy Treatment in 30 patients with 
bronchial carcinoma, São Paulo, SP, Brazil, 2012
*Paired t test; †Clinically-relevant scoring; ‡p<0.05; 
Table 4 – Comparison of Mean Scores for the QLQ-LC13 Pre- and Post-Chemotherapy Treatment in thirty patients with 
bronchial carcinoma, São Paulo, SP, Brazil, 2012
Pre-Chemotherapy Post-Chemotherapy
∆ t* pN=30 N=30
Mean SD Mean SD
Pain in Arm/ Shoulder 21.1 30.9 8.8 23.0 12.3† 2.00 0.054
Thoracic  pain 17.7 32.4 7.7 18.9 10.0† 1.43 0.163
Cough 51.1 31.2 42.2 31.4 8.9† 1.49 0.147
Hemoptysis 8.8 23.0 0 0 8.8† 2.11 0.043‡
Dyspnea 29.6 23.2 26.3 26.0 3.3 0.66 0.510
Dysphagia 4.4 14.4 2.2 8.4 2.2 0.70 0.489
Stomatitis 3.3 18.2 3.3 10.1 0.0 0.00 1.000
Pain in other parts 35.5 39.0 41.1 39.8 -5.6† -0.58 0.562
Sensory neuropathy 14.4 25.7 23.3 26.4 -8.9† -1.21 0.234
Alopecia 5.5 19.7 30.0 35.39 -24.5† -3.95 0.000‡
*Paired t test; †Clinically-relevant scoring; ‡ p<0.05
In Figure 1, it may be observed that the patients’ 
survival varied from 4 to 20 months with a median of 
10.5 months. The mortality rate was 63.3% with 19 
deaths.
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Discussion
In the present study, one can observe a 
predominance of men with an average age of 68. 
The incidence rates for lung cancer hit the age range 
between 50 and 70 years old and, generally, are higher 
among men than among women(15).
In the clinical characterization of the sample, 
the authors observed a large number of patients who 
smoked or were ex-smokers (83%). The disease was 
detected at an advanced stage in 53% of the patients. 
In the evaluation of the Karnofsky Scale, there was an 
average decline of four points over the course of the 
treatment. Regarding the chemotherapy treatment, 53% 
of the patients responded to the treatment, and due to 
the good Performance Status of this sample’s patients, 
the most-used chemotherapy protocol was Cisplatin + 
Gemcitabine (63%). During the study, 63.3% of the 
patients died, showing the disease’s high lethality. The 
median survival was 10.5 months. 
The treatment of choice for patients in whom the 
disease is advanced is Adjuvant chemotherapy(7). In 
the present study, the authors opted for selection of 
patients with stage IIIB and IV, because these patients 
are generally prescribed chemotherapy treatment 
exclusively, as the association of two therapeutic 
modalities could configure a bias in the assessment of 
the QLRH related to chemotherapy treatment.  
Due to the difficulty in obtaining large samples of 
this population, various studies have been undertaken 
with the aim of developing a standard for interpreting the 
results from QLRH questionnaires(14,16). The interpretation 
of clinical significance is one of the options for assessing 
results described in the EORTC’s Guidelines, which 
considers a difference of values from 5 to 10 points to 
be clinically relevant(13). The present study undertook 
the assessment of the QLRH through statistical and 
clinically-relevant significance. The classification made 
by the EORTC’s QL group was used as a benchmark for 
the assessment of clinically-relevant significance, and it 
was considered that a difference of 5 to 10 points has 
an impact on the patient’s clinical response. Considering 
statistical significance, the authors found an improvement 
only in the symptoms of dyspnea and hemoptysis, and 
a worsening for alopecia, while for the assessment of 
clinical significance, one can observe a higher number of 
changes in the QLRH. These differences may be related to 
the size of the sample, due to the disease’s high lethality 
index, and due to the difficulty of detecting changes both 
over time and among the groups of patients studied(14). 
Figure 1 – Survival curve in thirty patients with bronchial 
carcinoma, São Paulo, SP, Brazil, 2012
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For patients with lung cancer to maintain or 
improve their QL is as important as their survival time. 
In one study carried out with the aim of assessing 
chemotherapy’s impact on patients’ quality of life, the 
assessment of QL was undertaken with the EORTC 
QLQ C-30 questionnaire, with the lung-cancer-specific 
module LC-17, and by daily diary cards in two groups 
of patients: without chemotherapy (n=138) and with 
chemotherapy (n=135). The study demonstrated there 
to be no significant differences between the groups, 
concluding that the chemotherapy does not have a 
significant impact on the patients’ QL(3).
The findings of the present study demonstrate that 
the patients’ QLRH improved after the chemotherapy 
treatment. Similar data was found in two studies from 
outside Brazil which assessed the impact of different 
chemotherapy regimes on the QLRH of patients 
with lung cancer. The results indicate that the main 
chemotherapeutic medications available on the market 
improve the patients’ QLRH and alleviate the symptoms 
of cancer(17-18). 
Dyspnea is one of the three symptoms mentioned 
most by patients with lung cancer. In the present study, 
dyspnea was reported by 57% of the patients at the 
time of their diagnosis, and after chemotherapy there 
was an improvement in this symptom. Studies show 
that dyspnea is a strong predictor of the QLRH(19-20).
Sleep disturbances are a common problem in 
cancer patients(21). This sample’s patients, however, 
presented an improvement in the symptom of insomnia 
after the third cycle of chemotherapy. This higher level 
of difficulty in sleeping at the start of treatment may be 
explained by the worry about the disease and anxiety 
about chemotherapy. 
The pain associated with lung cancer may be 
triggered by various factors, such as the progression 
of the disease, or may be related to the therapeutic 
modality(22). In this study the authors observed an 
improvement in pain in the arm/shoulder and thorax; 
however, there was a worsening of pain in other parts 
and peripheral neuropathy after treatment. 
Alterations in the gastro-intestinal tract are 
frequently observed during chemotherapy, and vary 
according to the medication used. Currently, the 
chemotherapeutics in clinical use are tolerated well by 
the patients and have a low toxicity(3). However, the 
worsening found in this study of the symptoms of fatigue, 
nausea and vomiting, loss of appetite and alopecia after 
chemotherapy treatment were also observed in another 
study carried out, in which the patients who received 
chemotherapy treatment exclusively has a greater 
incidence of these symptoms when compared to patients 
who received radiotherapy exclusively(23).
Currently, the QLRH questionnaires must meet 
a set of criteria and attributes so as to ensure a 
reliable measurement(24). It is recommendable that the 
assessment of internal consistency should be undertaken 
whenever the instrument is used so as to analyze its 
behavior in different samples and environments(25). 
In this study, the instrument for assessing the QLRH 
demonstrated low rates of reliability in the pain scales, 
the scale for physical function and nausea and vomiting, 
in a way similar to what was verified in other studies(10-11). 
It is very difficult to undertake prospective studies 
with people with lung cancer, due to the disease’s high 
lethality. A high number of losses may be observed 
in this sample due to deaths which occurred while 
chemotherapy treatment was taking place. In terms 
of clinical relevance, the authors observed important 
alterations in the patients’ QLRH which were not 
confirmed by the statistical tests, probably due to the 
sample size.  
Conclusion
In relation to the alterations in the QLRH of the 
patients with lung cancer after chemotherapy treatment, 
the authors conclude that there was a clinically-
relevant improvement in the QLRH, financial difficulties, 
and in the symptoms of dyspnea, insomnia, cough, 
hemoptysis, thoracic pain and pain in the arm/shoulder. 
However, there was worsening of the functional scale of 
role performance and in the symptoms of constipation, 
alopecia, fatigue, nausea and vomiting, sensory 
neuropathy, pain in other parts and loss of appetite. The 
patients had improvement in the QLRH and symptoms 
related to lung cancer after chemotherapy treatment, 
however, there was worsening of symptoms resulting 
from the toxicity of the chemotherapeutic medications. 
The results obtained in the assessments of QLRH can 
be an important tool for guiding the health team’s 
interventions in the domains of the QLRH which are most 
affected according to the therapeutic modality chosen 
and the patient’s clinical progression. Further studies 
with larger samples must be undertaken to confirm the 
results obtained in this study. 
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